<DOC>
	<DOCNO>NCT02311881</DOCNO>
	<brief_summary>The purpose study determine whether paracetamol 1000 mg sustained-release ( SR ) tablet administer orally , twice daily effective safe treatment patient osteoarthritis knee hip .</brief_summary>
	<brief_title>A 12-Week Efficacy Study Paracetamol 1000mg Sustained-release Tablets Patients With Osteoarthritis</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>Male female participant 40 80 year age Diagnosis moderate moderatelysevere osteoarthritis ( OA ) either knee hip respect follow : Pain one knee/hip 3 month immediately screen visit Use non steroidal antiinflammatory drug ( NSAIDs ) , acetaminophen ( paracetamol ) analgesic 3 day per week least 3 month prior screen visit Clinical diagnosis osteoarthritis knee/hip minimum 6 month duration prior screen visit Therapeutic benefit acetaminophen use score ≥ 1 5point categorical scale Radiological evidence ≥ Grade 2 osteoarthritis accord KellgrenLawrence radiographic criterion Increased WOMAC Pain Subscale score least 20 % follow untreated runin period Moderate moderatelysevere selfreported pain 5point categorical scale follow untreated runin period Historical selfreported positive therapeutic benefit paracetamol use osteoarthritis pain relief History surgery major trauma study joint Clinically significant sign symptom inflammation upon completion runin period Required ongoing use analgesic therapy indication , anticoagulant , psychotherapeutic agent , aspirin daily dos great 325 mg , statinclass hypolipidemic agent dose stabilize , treatment know interfere pain perception History hepatic renal liver biliary disease gastrointestinal surgery Participants alanine aminotransferase ( ALT ) &gt; 2 time Upper Limit Normal ( 2xULN ) bilirubin &gt; 1.5 time Upper Limit Normal ( 1.5xULN ) ( However , direct bilirubin &lt; 35 % fraction , isolated bilirubin &gt; 1.5xULN acceptable ) Other arthritis type , fibromyalgia collagen vascular disease secondary OA study joint chronic pain condition</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>